The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990–2017*
Abstract
The global prevalence rate of AD has remained stable from 1990 to 2017. However, the distribution of AD by age groups shows a bimodal curve with the highest peak in early childhood, decreasing in prevalence among young adults, and a second peak in middle-aged and older populations. We also found a moderate positive correlation between a country's gross domestic product and disease burden. GBD data confirm the substantial worldwide burden of AD, which has remained stable since 1990 but shows significant geographical variation. Lifestyle factors, partially linked to affluence, are likely important disease drivers. However, the GBD methodology needs to be developed further to incorporate environmental risk factors, such as ultraviolet exposure, to understand better the geographical and age-related variations in disease burden.
MeSH terms
Funding
- Pfizer
- Sanofi
- University of Washington
- King’s College London
- Institute for Health Metrics and Evaluation
- National Institute for Health and Care Research
- King's College London
- European Commission
- Pfizer Pharmaceuticals
How this paper connects to the literature. Drag to explore, click any node to open that paper.
